DNA vaccine-PCV
US6943152B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 31, 2000 |
| Grant date | Sep 13, 2005 |
| Priority date | — |
| Expiry date | May 31, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/10034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to immunogenic preparations or vaccines comprising, on the one hand, a plasmid encoding and expressing a gene from PCV, in particular selected from the group consisting of ORF1 of PCV-2, ORF2 of PCV-2, ORF1 of PCV-1 and ORF2 of PCV-1, and, on the other hand, an element capable of increasing the immune response directed against the product of expression of the gene, which can be a carbomer, a porcine cytokine, e.g. GM-CSF or a cationic lipid of formula in which R1 is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R2 is another aliphatic radical comprising from 2 to 3 carbon atoms, andt X is an hydroxyle ou amine group. The cationic lipid can be DMRIE, possibly coupled with DOPE.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.